{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T18:42:56Z","timestamp":1784140976419,"version":"3.55.0"},"reference-count":58,"publisher":"IMR Press","issue":"3","license":[{"start":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T00:00:00Z","timestamp":1646352000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Biosci. (Landmark Ed)"],"abstract":"<jats:p>Pituitary adenomas (PA), or pituitary neuroendocrine tumors (PitNETs), represent 15% of all central nervous system tumors. Classic description of PitNETs solely by hormonal classification has given way to key transcription factors that play a role in the pathology of PitNETs including steroidogenic factor-1 (SF-1), t-box pituitary transcription factor (TPIT), and pituitary transcription factor 1 (PIT-1). Germline mutations in various familial PitNETs are discussed including those in familial isolated pituitary adenoma (FIPA), multiple endocrine neoplasia (MEN), neurofibromatosis 1 (NF1), and Carney complex. Recent advances in next generation sequencing have improved insight into the pathogenesis of PitNETs. A review of key studies in evaluating the genomic analysis of PitNETs was performed. Chromosomal mutations, whole exome sequencing, microRNA genomics, methylomics and transcriptomics were analyzed. Moreover, the multiomic analysis of various genomic panels has helped to better understand PA classification.<\/jats:p>","DOI":"10.31083\/j.fbl2703077","type":"journal-article","created":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T05:28:02Z","timestamp":1647581282000},"source":"Crossref","is-referenced-by-count":20,"title":["A review of multiomics platforms in pituitary adenoma pathogenesis"],"prefix":"10.31083","volume":"27","author":[{"given":"Nikolaos","family":"Mouchtouris","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupert D.","family":"Smit","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keenan","family":"Piper","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giyarpuram","family":"Prashant","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Evans","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Karsy","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, University of Utah, Salt Lake City, UT 84132, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2022,3,4]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Melmed S. Pituitary-Tumor Endocrinopathies. New England Journal of Medicine. 2020; 382: 937\u2013950.","DOI":"10.1056\/NEJMra1810772"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Raverot G, Jouanneau E, Trouillas J. Management of endocrine disease: Clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies. European Journal of Endocrinology. 2014; 170: R121\u2013R132.","DOI":"10.1530\/EJE-13-1031"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Lopes MBS. The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta Neuropathologica. 2017; 134: 521\u2013535.","DOI":"10.1007\/s00401-017-1769-8"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 who Classification of Tumors of the Central Nervous System: a summary. Neuro-Oncology. 2021; 23: 1231\u20131251.","DOI":"10.1093\/neuonc\/noab106"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Trouillas J, Jaffrain-Rea ML, Vasiljevic A, Raverot G, Roncaroli F, Villa C. How to Classify the Pituitary Neuroendocrine Tumors (PitNET)s in 2020. Cancers. 2020; 12: 514.","DOI":"10.3390\/cancers12020514"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Nishioka H, Inoshita N. New who classification of pituitary adenomas (4th edition): assessment of pituitary transcription factors and the prognostic histological factors. Brain Tumor Pathology. 2018; 35: 57\u201361.","DOI":"10.1007\/s10014-017-0307-7"},{"key":"ref7","unstructured":"Drummond JB, Ribeiro-Oliveira A Jr, Soares BS. Non-Functioning Pituitary Adenomas. 2000. Available at: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK534880\/ (Accessed: 12 August 2021)."},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Villa C, Vasiljevic A, Jaffrain-Rea ML, Ansorge O, Asioli S, Barresi V, et al. A standardised diagnostic approach to pituitary neuroendocrine tumours (PitNETs): a European Pituitary Pathology Group (EPPG) proposal. Virchows Archiv. 2019; 475: 687\u2013692.","DOI":"10.1007\/s00428-019-02655-0"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Nishioka H, Inoshita N, Sano T, Fukuhara N, Yamada S. Correlation between Histological Subtypes and MRI Findings in Clinically Nonfunctioning Pituitary Adenomas. Endocrine Pathology. 2012; 23: 151\u2013156.","DOI":"10.1007\/s12022-012-9208-9"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Erickson D, Scheithauer B, Atkinson J, Horvath E, Kovacs K, Lloyd RV, et al. Silent subtype 3 pituitary adenoma: a clinicopathologic analysis of the Mayo Clinic experience. Clinical Endocrinology. 2009; 71: 92\u201399.","DOI":"10.1111\/j.1365-2265.2008.03514.x"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Cooper O. Silent corticotroph adenomas. Pituitary. 2015; 18: 225\u2013231.","DOI":"10.1007\/s11102-014-0624-3"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"George DH, Scheithauer BW, Kovacs K, Horvath E, Young, WF, Lloyd RV, et al. Crooke\u2019s Cell Adenoma of the Pituitary: an aggressive variant of corticotroph adenoma. The American Journal of Surgical Pathology. 2003; 27: 1330\u20131336.","DOI":"10.1097\/00000478-200310000-00005"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Inomoto C, Tahara S, Oyama K, Kimura M, Matsuno A, Teramoto A, et al. Molecular, functional, and histopathological classification of the pituitary neuroendocrine neoplasms. Brain Tumor Pathology. 2021; 38: 183\u2013188.","DOI":"10.1007\/s10014-021-00410-5"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Drummond J, Roncaroli F, Grossman AB, Korbonits M. Clinical and Pathological Aspects of Silent Pituitary Adenomas. The Journal of Clinical Endocrinology & Metabolism. 2019; 104: 2473\u20132489.","DOI":"10.1210\/jc.2018-00688"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Cakir M, Grossman AB. Targeting MAPK (Ras\/ERK) and PI3K\/Akt pathways in pituitary tumorigenesis. Expert Opinion on Therapeutic Targets. 2009; 13: 1121\u20131134.","DOI":"10.1517\/14728220903170675"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Monsalves E, Juraschka K, Tateno T, Agnihotri S, Asa SL, Ezzat S, et al. The PI3K\/AKT\/mTOR pathway in the pathophysiology and treatment of pituitary adenomas. Endocrine-Related Cancer. 2014; 21: R331\u2013R344.","DOI":"10.1530\/ERC-14-0188"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Long R, Liu Z, Li J, Yu H. COL6a6 interacted with P4HA3 to suppress the growth and metastasis of pituitary adenoma via blocking PI3K-Akt pathway. Aging. 2019; 11: 8845\u20138859.","DOI":"10.18632\/aging.102300"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Duong CV, Emes RD, Wessely F, Yacqub-Usman K, Clayton RN, Farrell WE. Quantitative, genome-wide analysis of the DNA methylome in sporadic pituitary adenomas. Endocrine-Related Cancer. 2012; 19: 805\u2013816.","DOI":"10.1530\/ERC-12-0251"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Kober P, Boresowicz J, Rusetska N, Maksymowicz M, Goryca K, Kunicki J, et al. DNA methylation profiling in nonfunctioning pituitary adenomas. Molecular and Cellular Endocrinology. 2018; 473: 194\u2013204.","DOI":"10.1016\/j.mce.2018.01.020"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Taniguchi-Ponciano K, Andonegui-Elguera S, Pe\u00f1a-Mart\u00ednez E, Silva-Rom\u00e1n G, Vela-Pati\u00f1o S, Gomez-Apo E, et al. Transcriptome and methylome analysis reveals three cellular origins of pituitary tumors. Scientific Reports. 2020; 10: 19373.","DOI":"10.1038\/s41598-020-76555-8"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nature Reviews Cancer. 2001; 1: 222\u2013231.","DOI":"10.1038\/35106065"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Chang M, Yang C, Bao X, Wang R. Genetic and Epigenetic Causes of Pituitary Adenomas. Frontiers in Endocrinology. 2021; 11: 596554.","DOI":"10.3389\/fendo.2020.596554"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Neou M, Villa C, Armignacco R, Jouinot A, Raffin-Sanson M, Septier A, et al. Pangenomic Classification of Pituitary Neuroendocrine Tumors. Cancer Cell. 2020; 37: 123\u2013134.e5.","DOI":"10.1016\/j.ccell.2019.11.002"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Nishioka H, Inoshita N, Mete O, Asa SL, Hayashi K, Takeshita A, et al. The Complementary Role of Transcription Factors in the Accurate Diagnosis of Clinically Nonfunctioning Pituitary Adenomas. Endocrine Pathology. 2015; 26: 349\u2013355.","DOI":"10.1007\/s12022-015-9398-z"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Mete O, Asa SL. Structure, Function, and Morphology in the Classification of Pituitary Neuroendocrine Tumors: the Importance of Routine Analysis of Pituitary Transcription Factors. Endocrine Pathology. 2020; 31: 330\u2013336.","DOI":"10.1007\/s12022-020-09646-x"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Hong SW, Kim SH, Lim SH, Lee EJ, Kim SH, Ku CR, et al. Clinical Relevance of New World Health Organization Classification System for Pituitary Adenomas: A Validation Study With 2-Year Experience. Frontiers in Oncology. 2021; 11: 739290.","DOI":"10.3389\/fonc.2021.739290"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Mart\u00ednez A, Sottile J, S\u00e1nchez-Tejada L, Fajardo C, C\u00e1mara R, Lamas C, et al. DNA Methylation of Tumor Suppressor Genes in Pituitary Neuroendocrine Tumors. The Journal of Clinical Endocrinology & Metabolism. 2019; 104: 1272\u20131282.","DOI":"10.1210\/jc.2018-01856"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Principe M, Chanal M, Ilie MD, Ziverec A, Vasiljevic A, Jouanneau E, et al. Immune Landscape of Pituitary Tumors Reveals Association between Macrophages and Gonadotroph Tumor Invasion. The Journal of Clinical Endocrinology & Metabolism. 2020; 105: 3459\u20133473.","DOI":"10.1210\/clinem\/dgaa520"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Song Z, Reitman ZJ, Ma Z, Chen J, Zhang Q, Shou X, et al. The genome-wide mutational landscape of pituitary adenomas. Cell Research. 2016; 26: 1255\u20131259.","DOI":"10.1038\/cr.2016.114"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Albani A, P\u00e9rez-Rivas LG, Dimopoulou C, Zopp S, Col\u00f3n-Bolea P, Roeber S, et al. The USP8 mutational status may predict long-term remission in patients with Cushing\u2019s disease. Clinical Endocrinology. 2018. (in press)","DOI":"10.1111\/cen.13802"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Salomon MP, Wang X, Marzese DM, Hsu SC, Nelson N, Zhang X, et al. The Epigenomic Landscape of Pituitary Adenomas Reveals Specific Alterations and Differentiates among Acromegaly, Cushing\u2019s Disease and Endocrine-Inactive Subtypes. Clinical Cancer Research. 2018; 24: 4126\u20134136.","DOI":"10.1158\/1078-0432.CCR-17-2206"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Luo P, Zhang L, Yang L, An Z, Tan H. Progress in the Pathogenesis, Diagnosis, and Treatment of TSH-Secreting Pituitary Neuroendocrine Tumor. Frontiers in Endocrinology. 2020; 11: 580264.","DOI":"10.3389\/fendo.2020.580264"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Thakker RV, Newey PJ, Walls GV, Bilezikian J, Dralle H, Ebeling PR, et al. Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1). The Journal of Clinical Endocrinology & Metabolism. 2012; 97: 2990\u20133011.","DOI":"10.1210\/jc.2012-1230"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Thakker RV. Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4). Molecular and Cellular Endocrinology. 2014; 386: 2\u201315.","DOI":"10.1016\/j.mce.2013.08.002"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Bogus\u0142awska A, Korbonits M. Genetics of Acromegaly and Gigantism. Journal of Clinical Medicine. 2021; 10: 1377.","DOI":"10.3390\/jcm10071377"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Delgrange E, Sassolas G, Perrin G, Jan M, Trouillas J. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance. Acta Neurochirurgica. 2005; 147: 751\u2013758.","DOI":"10.1007\/s00701-005-0498-2"},{"key":"ref37","unstructured":"Schaller B. Gender-related differences in prolactinomas. A clinicopathological study. Neuro Endocrinology Letters. 2005; 26: 152\u2013159."},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Nishioka H, Haraoka J, Akada K, Azuma S. Gender-related differences in prolactin secretion in pituitary prolactinomas. Neuroradiology. 2002; 44: 407\u2013410.","DOI":"10.1007\/s00234-002-0774-2"},{"key":"ref39","unstructured":"Holbrook L, Brady R. McCune Albright Syndrome. 2022. Available at: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK537092\/ (Accessed: 13 August 2021)."},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Salenave S, Boyce AM, Collins MT, Chanson P. Acromegaly and McCune-Albright Syndrome. The Journal of Clinical Endocrinology & Metabolism. 2014; 99: 1955\u20131969.","DOI":"10.1210\/jc.2013-3826"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Kamilaris C, Faucz F, Voutetakis A, Stratakis C. Carney Complex. Experimental and Clinical Endocrinology & Diabetes. 2019; 127: 156\u2013164.","DOI":"10.1055\/a-0753-4943"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Bertherat J, Horvath A, Groussin L, Grabar S, Boikos S, Cazabat L, et al. Mutations in Regulatory Subunit Type 1a of Cyclic Adenosine 5\u2032-Monophosphate-Dependent Protein Kinase (PRKAR1a): Phenotype Analysis in 353 Patients and 80 Different Genotypes. The Journal of Clinical Endocrinology & Metabolism. 2009; 94: 2085\u20132091.","DOI":"10.1210\/jc.2008-2333"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Forlino A, Vetro A, Garavelli L, Ciccone R, London E, Stratakis CA, et al. PRKACB and Carney Complex. New England Journal of Medicine. 2014; 370: 1065\u20131067.","DOI":"10.1056\/NEJMc1309730"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Lonser RR, Mehta GU, Kindzelski BA, Ray-Chaudhury A, Vortmeyer AO, Dickerman R, et al. Surgical Management of Carney Complex\u2013Associated Pituitary Pathology. Neurosurgery. 2017; 80: 780\u2013786.","DOI":"10.1227\/NEU.0000000000001384"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Hern\u00e1ndez-Ram\u00edrez LC, Gam R, Vald\u00e9s N, Lodish MB, Pankratz N, Balsalobre A, et al. Loss-of-function mutations in the CABLES1 gene are a novel cause of Cushing\u2019s disease. Endocrine-Related Cancer. 2017; 24: 379\u2013392.","DOI":"10.1530\/ERC-17-0131"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Zhang Q, Peng C, Song J, Zhang Y, Chen J, Song Z, et al. Germline Mutations in CDH23, Encoding Cadherin-Related 23, are Associated with both Familial and Sporadic Pituitary Adenomas. The American Journal of Human Genetics. 2017; 100: 817\u2013823.","DOI":"10.1016\/j.ajhg.2017.03.011"},{"key":"ref47","unstructured":"Iacovazzo D, Korbonits M. X-Linked Acrogigantism. 1993. Available at: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK476671\/ (Accessed: 14 August 2021)."},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Iacovazzo D, Caswell R, Bunce B, Jose S, Yuan B, Hern\u00e1ndez-Ram\u00edrez LC, et al. Germline or somatic GPR101 duplication leads to X-linked acrogigantism: a clinico-pathological and genetic study. Acta Neuropathologica Communications. 2016; 4: 56.","DOI":"10.1186\/s40478-016-0328-1"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Xekouki P, Szarek E, Bullova P, Giubellino A, Quezado M, Mastroyannis SA, et al. Pituitary Adenoma with Paraganglioma\/Pheochromocytoma (3PitNETs) and Succinate Dehydrogenase Defects in Humans and Mice. The Journal of Clinical Endocrinology & Metabolism. 2015; 100: E710\u2013E719.","DOI":"10.1210\/jc.2014-4297"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Rostomyan L, Daly AF, Petrossians P, Nachev E, Lila AR, Lecoq A, et al. Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients. Endocrine-Related Cancer. 2015; 22: 745\u2013757.","DOI":"10.1530\/ERC-15-0320"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Rodd C, Millette M, Iacovazzo D, Stiles CE, Barry S, Evanson J, et al. Somatic GPR101 Duplication Causing X-Linked Acrogigantism (XLAG)-Diagnosis and Management. The Journal of Clinical Endocrinology and Metabolism. 2016; 101: 1927\u20131930.","DOI":"10.1210\/jc.2015-4366"},{"key":"ref52","unstructured":"Kurozumi K, Tabuchi A, Ono Y, Tamiya T, Ohmoto T, Furuta T, et al. Pituitary adenoma associated with neurofibromatosis type 1: case report. No Shinkei Geka. Neurological Surgery. 2002; 30: 741\u2013745. (In Japanese)"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Tatsi C, Stratakis CA. The Genetics of Pituitary Adenomas. Journal of Clinical Medicine. 2019; 9: 30.","DOI":"10.3390\/jcm9010030"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"O\u2019Toole SM, D\u00e9nes J, Robledo M, Stratakis CA, Korbonits M. 15 YEARS of PARAGANGLIOMA: the association of pituitary adenomas and phaeochromocytomas or paragangliomas. Endocrine-Related Cancer. 2015; 22: T105\u2013T122.","DOI":"10.1530\/ERC-15-0241"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Daly AF, Castermans E, Oudijk L, Guitelman MA, Beckers P, Potorac I, et al. Pheochromocytomas and pituitary adenomas in three patients with MAX exon deletions. Endocrine-Related Cancer. 2018; 25: L37\u2013L42.","DOI":"10.1530\/ERC-18-0065"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"D\u00e9nes J, Swords F, Rattenberry E, Stals K, Owens M, Cranston T, et al. Heterogeneous Genetic Background of the Association of Pheochromocytoma\/Paraganglioma and Pituitary Adenoma: Results from a Large Patient Cohort. The Journal of Clinical Endocrinology & Metabolism. 2015; 100: E531\u2013E541.","DOI":"10.1210\/jc.2014-3399"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Dwight T, Mann K, Benn DE, Robinson BG, McKelvie P, Gill AJ, et al. Familial SDHA Mutation Associated with Pituitary Adenoma and Pheochromocytoma\/Paraganglioma. The Journal of Clinical Endocrinology & Metabolism. 2013; 98: E1103\u2013E1108.","DOI":"10.1210\/jc.2013-1400"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Guerrero-P\u00e9rez F, Fajardo C, Torres Vela E, Gim\u00e9nez-Palop O, Lisbona Gil A, Mart\u00edn T, et al. 3P association (3PitNETs): Pituitary adenoma and pheochromocytoma\/paraganglioma. A heterogeneous clinical syndrome associated with different gene mutations. European Journal of Internal Medicine. 2019; 69: 14\u201319.","DOI":"10.1016\/j.ejim.2019.08.005"}],"container-title":["Frontiers in Bioscience-Landmark"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/27\/3\/10.31083\/j.fbl2703077","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T06:34:05Z","timestamp":1732689245000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/27\/3\/10.31083\/j.fbl2703077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,4]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"alternative-id":["S2768-6701(22)00415-4"],"URL":"https:\/\/doi.org\/10.31083\/j.fbl2703077","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.741964450.793594251","asserted-by":"object"}]},"ISSN":["2768-6701","2768-6698"],"issn-type":[{"value":"2768-6701","type":"print"},{"value":"2768-6698","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,4]]},"article-number":"77"}}